Viral Vector Potency Assay Using Reporter T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining viral vector potency are costly, imprecise, and not easily reproducible, leading to significant variability in vector effectiveness, particularly in adoptive immunotherapy for cancer, infectious diseases, and autoimmune diseases.
Innovation Solution
A method involving the introduction of a titrated amount of a test viral vector into reporter T cells expressing a recombinant receptor with an intracellular signaling region, followed by incubation with a stimulating agent to induce a detectable signal from a reporter molecule, allowing for the determination of half-maximal potency through measurable luciferase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for determining viral vector potency are used, then the assessment can be performed, but the methods are costly, imprecise, and not easily reproducible
Solution Approach 1:
The patent introduces reporter cells as intermediary objects that contain both the recombinant receptor and a reporter molecule (e.g., luciferase). These reporter cells serve as a mediator between the viral vector and the measurement system, allowing indirect but precise measurement of vector potency through the reporter signal rather than direct measurement methods that are costly and imprecise.
Solution Approach 2:
The patent replaces complex mechanical/cellular assay systems with a biochemical measurement system. Instead of using complex functional assays that are costly and imprecise, the invention uses a simplified measurement of reporter molecule activity (e.g., luciferase luminescence) that provides precise and reproducible potency data.
2Measurement precision
If current methods are used to assess viral vector potency, then potency determination is possible, but significant unwanted variation between lots occurs
Solution Approach 1:
The patent implements a feedback mechanism where the reporter cell signal provides a quantitative readout of viral vector potency. By measuring the reporter molecule activity and comparing it against reference values, the system provides feedback that allows for precise potency determination and reduces lot-to-lot variation through standardized measurement and normalization.
Solution Approach 2:
The patent changes the measurement parameter from direct functional assays to reporter molecule activity levels. This parameter change enables more precise and consistent potency measurement by using the reporter signal intensity as a quantitative proxy for vector effectiveness, reducing unwanted variation between production lots.
3Productivity
If high-throughput assessment is implemented, then productivity increases, but measurement precision may be compromised
Solution Approach 1:
The patent uses reporter cells as standardized copies that contain the recombinant receptor and reporter molecule. These reporter cells serve as uniform test subjects that can be processed in high-throughput formats (e.g., 96-well plates) while maintaining measurement precision, as each cell copy contains the same genetic construct and signaling pathway for consistent reporter activation.
Solution Approach 2:
The patent changes the assay format to accommodate high-throughput processing while maintaining precision. By using soluble reporter molecules that can be measured in bulk (e.g., luminescence assays), the system enables parallel processing of multiple samples simultaneously without compromising measurement accuracy, thus increasing productivity while preserving precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable, high-throughput method for assessing viral vector potency with reduced variability, enabling consistent and efficient production of viral vectors for cell and gene therapies.
Implementation Method 1
binding of the recombinant receptor stimulating agent to the recombinant receptor induces signaling through the intracellular signaling region of the recombinant receptor to produce a detectable signal from the reporter molecule
Implementation Method 2
measuring each of the plurality of populations of reporter T cells for the detectable signal from the reporter molecule
Data Source
AI summary
Provided herein are cells, methods, kits and articles of manufacture, including those related to assessing the potency of viral vectors. The present disclosure relates to a method for screening for potency of a viral vector, including vectors which encode recombinant receptors that contain an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR). The methods include assessing potency of a viral vector based on a detectable or measurable expression or activity of a reporter molecule(s) that are responsive to a signal through the intracellular signaling region of the T cell receptor e.g., recombinant receptor.